D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 106 Citations 53,236 431 World Ranking 2855 National Ranking 1652

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

Internal medicine, Lung cancer, Cancer research, Cancer and Oncology are his primary areas of study. His work on Immunotherapy, Carcinoma, Vismodegib and Phases of clinical research as part of general Internal medicine research is frequently linked to Response Evaluation Criteria in Solid Tumors, bridging the gap between disciplines. The Lung cancer study combines topics in areas such as Survival rate, Surgery, Immunology, KRAS and Hazard ratio.

His research integrates issues of Cell culture, Endocrinology, Cisplatin, EZH2 and Regulation of gene expression in his study of Cancer research. He has included themes like Gastroenterology, Adverse effect and Pathology, Histology in his Cancer study. Charles M. Rudin combines subjects such as Clinical endpoint, Clinical trial, Blockade, Nivolumab and Adenocarcinoma with his study of Oncology.

His most cited work include:

  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer (5007 citations)
  • Akt stimulates aerobic glycolysis in cancer cells (1130 citations)
  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (931 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Internal medicine, Cancer research, Oncology, Lung cancer and Cancer. His research combines Surgery and Internal medicine. His Cancer research research is multidisciplinary, incorporating elements of Cell, Carcinogenesis, Immunology, Pathology and In vivo.

In the field of Oncology, his study on Non small cell overlaps with subjects such as In patient. His studies in Lung cancer integrate themes in fields like Mutation, KRAS, Carcinoma, Targeted therapy and Adenocarcinoma. As part of his studies on Cancer, he frequently links adjacent subjects like Disease.

He most often published in these fields:

  • Internal medicine (45.80%)
  • Cancer research (47.38%)
  • Oncology (38.46%)

What were the highlights of his more recent work (between 2019-2021)?

  • Cancer research (47.38%)
  • Internal medicine (45.80%)
  • Oncology (38.46%)

In recent papers he was focusing on the following fields of study:

His main research concerns Cancer research, Internal medicine, Oncology, Lung cancer and Cancer. Charles M. Rudin interconnects Cell, ASCL1, Metastasis, PI3K/AKT/mTOR pathway and Adenocarcinoma in the investigation of issues within Cancer research. The various areas that Charles M. Rudin examines in his Oncology study include Pembrolizumab, Clinical trial, Disease and Exon.

He has included themes like Mutation, KRAS, STK11, Mutant and Germline in his Lung cancer study. The Cancer study combines topics in areas such as Lineage and Computational biology. His Immunotherapy study incorporates themes from Biomarker and Antigen presentation.

Between 2019 and 2021, his most popular works were:

  • Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers (83 citations)
  • Regenerative lineages and immune-mediated pruning in lung cancer metastasis (71 citations)
  • The Human Tumor Atlas Network: Charting Tumor Transitions Across Space and Time at Single-Cell Resolution (65 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His primary scientific interests are in Internal medicine, Cancer research, Lung cancer, Oncology and Cancer. His Cancer research research integrates issues from Immunohistochemistry, Trastuzumab, Cellular differentiation, Tumor progression and Internalization. The study incorporates disciplines such as Tyrosine kinase, Receptor, Endocytosis, Mutant and Cytotoxic T cell in addition to Lung cancer.

His work carried out in the field of Oncology brings together such families of science as Concurrent chemoradiation, Blockade and Immunotherapy. He has researched Immunotherapy in several fields, including Mutation, Missense mutation, KRAS, STK11 and Biomarker. The concepts of his Cancer study are interwoven with issues in Exosome, Cell and Proteomic Profile.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei;L. Paz-Ares;L. Horn;D. R. Spigel.
The New England Journal of Medicine (2015)

6521 Citations

Akt stimulates aerobic glycolysis in cancer cells

Rebecca L. Elstrom;Daniel E. Bauer;Monica Buzzai;Robyn Karnauskas.
Cancer Research (2004)

1516 Citations

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
JAMA (2014)

1262 Citations

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulic;Michael R. Migden;Anthony E. Oro;Luc Dirix.
The New England Journal of Medicine (2012)

1246 Citations

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

Daniel D. Von Hoff;Patricia M. LoRusso;Charles M. Rudin;Josina C. Reddy.
The New England Journal of Medicine (2009)

1216 Citations

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

Charles M. Rudin;Christine L. Hann;John Laterra;Robert L. Yauch.
The New England Journal of Medicine (2009)

1091 Citations

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Federico Innocenti;Samir D. Undevia;Lalitha Iyer;Pei Xian Chen.
Journal of Clinical Oncology (2004)

1072 Citations

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann.
Nature Genetics (2019)

999 Citations

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma

Robert L. Yauch;Gerrit J. P. Dijkgraaf;Bruno Alicke;Thomas Januario.
Science (2009)

879 Citations

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Charles M Rudin;Steffen Durinck;Eric W Stawiski;John T Poirier.
Nature Genetics (2012)

819 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Charles M. Rudin

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 129

Ignacio I. Wistuba

Ignacio I. Wistuba

The University of Texas MD Anderson Cancer Center

Publications: 82

Matthew D. Hellmann

Matthew D. Hellmann

Memorial Sloan Kettering Cancer Center

Publications: 81

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 76

Fabrice Barlesi

Fabrice Barlesi

Aix-Marseille University

Publications: 74

Caicun Zhou

Caicun Zhou

Tongji University

Publications: 74

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 72

John V. Heymach

John V. Heymach

The University of Texas MD Anderson Cancer Center

Publications: 71

Alexander Drilon

Alexander Drilon

Memorial Sloan Kettering Cancer Center

Publications: 69

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 67

Yi-Long Wu

Yi-Long Wu

Guangdong Provincial People’s Hospital

Publications: 64

Suresh S. Ramalingam

Suresh S. Ramalingam

Emory University

Publications: 63

Myung-Ju Ahn

Myung-Ju Ahn

Samsung Medical Center

Publications: 60

Solange Peters

Solange Peters

University Hospital of Lausanne

Publications: 60

Luis Paz-Ares

Luis Paz-Ares

Complutense University of Madrid

Publications: 60

Michael D. Taylor

Michael D. Taylor

University of Toronto

Publications: 59

Trending Scientists

Konrad Schindler

Konrad Schindler

ETH Zurich

Dorothy E. Leidner

Dorothy E. Leidner

Baylor University

Zhang-Cheng Hao

Zhang-Cheng Hao

Southeast University

Uri Shamir

Uri Shamir

Technion – Israel Institute of Technology

John W. Brady

John W. Brady

Cornell University

Joseph P. A. Harrity

Joseph P. A. Harrity

University of Sheffield

Gane Ka-Shu Wong

Gane Ka-Shu Wong

University of Alberta

Christophe Guinet

Christophe Guinet

University of La Rochelle

Ingo Heilmann

Ingo Heilmann

Martin Luther University Halle-Wittenberg

André Sobel

André Sobel

Inserm : Institut national de la santé et de la recherche médicale

Stephen M. Schueller

Stephen M. Schueller

University of California, Irvine

Deborah Grady

Deborah Grady

University of California, San Francisco

William Grossman

William Grossman

University of California, San Francisco

Berislav V. Zlokovic

Berislav V. Zlokovic

University of Southern California

Douglas B. Johnson

Douglas B. Johnson

Vanderbilt University Medical Center

Marko I. Turina

Marko I. Turina

University of Zurich

Something went wrong. Please try again later.